FAVOR III China: QFR-Guided PCI Strategy vs. Angiography-Guided Strategy

FAVOR III China has bees published on Lancet and simultaneously presented at TCT 2021

It’s the first randomized trial to compare the clinical outcomes of PCI guided by angiography-derived physiological lesion selection and standard angiography-guided lesion selection. QFR guidance resulted in a 35% risk reduction in the 1-year rate of major adverse cardiac events, a composite of death from any cause, myocardial infarction, or ischaemia driven revascularization, compared with standard angiography guidance. READ MORE

Latest News:

Gender matter! EUKON move on mission 5

Caserta, ITALY – August 8th, 2023   We are absolutely…

Read More >

EUKON FT1000 ranking 2022 on Financial Times

FT 1000: the sixth annual list of Europe’s fastest-growing companies…

Read More >

EUKON Leader della Crescita 2022

Leader della Crescita is  rank of first 450 companies, done…

Read More >